

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

19 November 2020 (19.11.2020)



(10) International Publication Number

WO 2020/229502 A1

(51) International Patent Classification:

A61K 31/135 (2006.01)

A61P 29/00 (2006.01)

A61K 31/415 (2006.01)

Published:

— with international search report (Art. 21(3))

(21) International Application Number:

PCT/EP2020/063250

(22) International Filing Date:

13 May 2020 (13.05.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

19382377.0

14 May 2019 (14.05.2019)

EP

(71) Applicant: ESTEVE PHARMACEUTICALS, S.A.

[ES/ES]; Passeig de la Zona Franca, 109, 4a Planta, 08038 Barcelona (ES).

(72) Inventors: ENCINA-GARCÍA, Gregorio-José; Santa

Carolina, 53-59, 1-2a, 08025 Barcelona (ES). PLATA-SALAMÁN, Carlos-Ramón; Carrer de Laforja 95, Àtico 2, 08021 Barcelona (ES).

(74) Agent: PETERS, Hajo et al.; Dehmel Et Bettenhausen

Patentanwälte PartmbB, Herzogspitalstraße 11, 80331 München (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: USE OF CO-CRYSTALS OF TRAMADOL AND CELECOXIB FOR TREATING PAIN WHILE REDUCING THE ABUSE LIABILITY OF TRAMADOL

(57) Abstract: The present invention relates to the use of co-crystals of tramadol and celecoxib for the treatment of pain, preventing the risk of an addiction to tramadol, for the treatment of pain while reducing the abuse liability of tramadol, for the treatment of pain also reducing an incidence of addiction to tramadol, for the treatment of pain preventing an addiction to tramadol, for the treatment of pain in a patient with an addiction to tramadol or the risk of it, for the treatment of pain and inhibiting, delaying, reducing or reversing an addiction to tramadol or for treatment of pain and reducing an incidence of addiction to tramadol.



WO 2020/229502 A1

**USE OF CO-CRYSTALS OF TRAMADOL AND CELECOXIB FOR TREATING PAIN
WHILE REDUCING THE ABUSE LIABILITY OF TRAMADOL**

The present invention relates to the use of co-crystals of tramadol and celecoxib for the treatment of pain, preventing the risk of an addiction to tramadol, for the treatment of pain while reducing the abuse liability of tramadol, for the treatment of pain also reducing an incidence of addiction to tramadol, for the treatment of pain preventing an addiction to tramadol, for the treatment of pain in a patient with an addiction to tramadol or the risk of it, for the treatment of pain and inhibiting, delaying, reducing or reversing an addiction to tramadol or for treatment of pain and reducing the incidence of an addiction to tramadol.

BACKGROUND

Pain is a complex response that has been functionally categorized into sensory, autonomic, motor, and affective components. The sensory aspect includes information about stimulus location and intensity while the adaptive component may be considered to be the activation of endogenous pain modulation and motor planning for escape responses. The affective component appears to include evaluation of pain unpleasantness and stimulus threat as well as negative emotions triggered by memory and context of the painful stimulus.

In general, pain conditions can be divided into chronic and acute. Chronic pain includes neuropathic pain and chronic inflammatory pain, for example arthritis, or pain of unknown origin, such as fibromyalgia. Acute pain usually follows non-neural tissue injury, for example tissue damage from surgery or inflammation, or migraine.

Recently co-crystals of tramadol and celecoxib have been discovered that are used for the treatment of pain. Examples of such co-crystals are published under PCT in WO2011/044962 and are very effective in the treatment of pain, especially in the treatment acute and chronic medium to severe pain.

Tramadol is a synthetic, centrally acting analgesic agent with 2 distinct, synergistic mechanisms of action. It is both a weak opioid agonist with selectivity for the μ -receptor and a weak inhibitor of the reuptake of noradrenaline (norepinephrine) and serotonin (5-hydroxytryptamine; 5-HT). Its analgesic potency is claimed to be about one tenth that of morphine. Tramadol is used to treat both acute and chronic pain of moderate to (moderately) severe intensity. Tramadol is considered to be a relatively safe analgesic and is widely used.

The main adverse reactions to tramadol therapy are nausea, dizziness, and vomiting, particularly at the start of the therapy. At therapeutic doses, tramadol does not cause clinically relevant respiratory depression. Tramadol is contra-indicated, however, in patients with diminished respiratory function. Tramadol is generally considered as a medicinal drug with a low potential for dependence relative to morphine. Nevertheless, tramadol dependence has been shown to occur when used for prolonged periods of time (more than several weeks to months). Dependence to tramadol may occur when used within the recommended dose range but especially when used at supra-therapeutic doses. At supra-therapeutic doses and rarely at therapeutic doses, intoxications may occur. Symptoms of tramadol intoxication are similar to those of other opioid analgesics but may include serotonergic and noradrenergic components. Symptoms include central nervous system (CNS) depression and coma, tachycardia, cardiovascular collapse, seizures, and respiratory depression up to respiratory arrest. Fatal intoxications are rare and appear to be associated with large overdoses of tramadol.

According to the DEA (United States Drug Enforcement Administration), drugs, substances, and certain chemicals used to make drugs are classified into five (5) distinct categories or schedules depending upon the drug's acceptable medical use and the drug's abuse or dependency potential. The abuse rate is a determinate factor in the scheduling of the drug; for example, Schedule I drugs have a high potential for abuse and the potential to create severe psychological and/or physical dependence. As the drug schedule changes-- Schedule II, Schedule III, etc., so does the abuse potential-- Schedule V drugs represent the least potential for abuse. A Listing of drugs and their schedule are located at Controlled Substance Act (CSA) Scheduling or CSA Scheduling by Alphabetical Order. These lists describe the basic or parent chemical and do not necessarily describe the salts, isomers and salts of isomers, esters, ethers and derivatives which may also be classified as controlled substances. These lists are intended as general references and are not comprehensive listings of all controlled substances.

Tramadol is listed in Schedule IV listing drugs with a low potential for abuse and low risk of dependence.

In an official definition by the FDA, Drug products with abuse potential generally contain drug substances that have central nervous system (CNS) activity and produce euphoria (or other changes in mood), hallucinations, and effects consistent with CNS depressants or stimulants. Thus, if a drug substance is CNS-active, the new drug product containing that drug substance may need to undergo a thorough assessment of its abuse potential and may be subject to

control, e.g. in the US under the Controlled Substances Act (CSA) (see generally 21 U.S.C. 811). Drug abuse is defined as the intentional, non-therapeutic use of a drug product or substance, even once, to achieve a desired psychological or physiological effect. Therefore, abuse potential refers to the likelihood that abuse will occur with a particular drug product or substance with CNS activity. Drug abuse is a serious public health problem that affects almost every community and family in some way. Each year drug abuse causes millions of serious illnesses or injuries among Americans. Abused drugs include methamphetamine, anabolic steroids, club drugs, cocaine, heroin, inhalants, marijuana, prescription drugs, including opioids. Drug abuse also plays a role in many major social problems, such as drugged driving, violence and stress. There are different types of treatments for drug abuse, one of them being to reduce the abuse potential of a drug by modifying its pharmacokinetics properties.

The World Health Organization (WHO) defines substance addiction as using a substance repeatedly, despite knowing and experiencing harmful effects. Substance addiction is a chronic, relapsing disease characterized by a loss of control over drug use, compulsive drug seeking and craving for a substance, use that persists despite negative consequences, and physical and/or psychological dependence on the substance. Substance abuse and addiction are public health issues.

On the other hand, opioid drugs such as tramadol are indispensable in the clinical management of pain syndromes.

Thus, there is a constant and urgent need to find alternative or improved pharmacological activities in the treatment of pain, being effective while exhibiting a reduced abuse potential of the drug. This naturally also applies to tramadol, which is widely used as a relatively safe analgesic.

SUMMARY OF THE INVENTION:

While investigating the potential of E-58425 in the treatment of pain, the applicant has highlighted that it lends itself to decrease the abuse liability of tramadol by modification of its pharmacokinetics properties.

The present invention is therefore related to the decrease of abuse liability of tramadol through the administration of a co-crystal of tramadol HCl and celecoxib. Thus, the application relates

in a major aspect to a co-crystal of (rac)-tramadol·HCl and celecoxib, or a pharmaceutically acceptable derivative thereof, for treating pain while reducing the abuse liability of tramadol.

It has surprisingly been found that co-crystals of tramadol and celecoxib like the co-crystal E-58425 treats pain while reducing the abuse liability compared to tramadol alone or to the combination of tramadol and celecoxib based on changes in its pharmacokinetic profile.

DETAILED DESCRIPTION:

The attractiveness of opioids for abuse is usually evaluated using validated measures of subjective pharmacodynamic (PD) effects (e.g. drug liking, drug high), as well as selected pharmacokinetic characteristics of opioids, such as peak plasma concentration (C_{max}) and time to achieve C_{max} , expressed as T_{max} (Harris et al., Pain Medicine; 18: 1278–1291 (2017) and Kopecky et al.; The Journal of Clinical Pharmacology, 57(4) 500–512 (2017)). In terms of PK, the literature states that for opioids there is high correlation of the C_{max}/T_{max} ratio called Abuse Quotient (AQ) and PD effects, with higher AQ denoting greater abuse potential.

Taken in that context, Harris et al. evaluated the oral abuse potential and pharmacokinetics (PK) of hydrocodone intact, chewed, or milled to fine particles in comparison with hydrocodone solution or placebo. The results of the PK analysis indicate that the rate of hydrocodone absorption, illustrated by the calculation C_{max}/T_{max} , decreased in parallel with the PD measures of abuse potential. These differences may be associated with lower abuse potential because the rate of increase in concentration of opioid in plasma (C_{max}/T_{max}) is suggested to be positively correlated with the likelihood of abuse.

In Kopecky et al., it is described that the abuse quotient is a measure of average rate of rise in plasma concentration between dosing and T_{max} ; the score is thought to be related to a product's abuse potential.

Harriet de Wit et al. (Psychopharmacology; 107: 352-358 (1992)) mentions that certain pharmacokinetic properties of drugs are believed to explain differences among drugs in liability for abuse. One of these properties is the rapidity with which the drug is delivered to the central nervous system. Different drugs within the same class are thought to differ in abuse liability because of this characteristic, and different routes of administration are thought to be associated with differential likelihood of abuse for similar reasons.

“Abuse liability” is defined as the propensity of a drug to produce compulsive use, to cause addiction, or the potential that a drug has for addiction. The term is used interchangeably with “potential for addiction”.

“Abuse potential” or “potential for abuse” is the likelihood that abuse will occur with a particular drug product or substance with central nervous system activity.

“Abuse” is defined as the intentional non-therapeutic use of a drug, even once, to achieve a desired psychological or physiological effect. That is, the use of a drug in a way that is not intended or recommended. Abuse can lead to addiction.

“(Drug) Addiction” is defined as a compulsive drug use despite harmful consequences characterized by an inability to stop using a drug.

It seems therefore that abuse liability is higher for drugs with a high $C_{\max}$ and short $T_{\max}$. The quotient $C_{\max}/T_{\max}$ is determinant in how a drug is a potential for addiction: the lower the AQ the lower the abuse liability.

It has surprisingly been found that co-crystal E-58425 shows a better (lower) AQ ratio compared to Tramadol alone or to the combination of tramadol and celecoxib (administered as the commercially available drug products), leading to the conclusion that the co-crystal E-58425 treats pain while reducing the abuse liability or potential for addiction compared to tramadol alone or to the combination of tramadol and celecoxib.

The application relates in a first major **Aspect A**) to a co-crystal of (rac)-tramadol·HCl and celecoxib, or a pharmaceutically acceptable derivative thereof, for treating pain while reducing the abuse liability of tramadol.

The application thus also relates in this major **Aspect A**) to a method for treating pain while reducing the abuse liability of tramadol, the method comprising administering to the subject a therapeutically effective dose of a co-crystal of (rac)-tramadol·HCl and celecoxib, or a pharmaceutically acceptable derivative thereof.

“Treating pain while reducing the abuse liability of tramadol” in the sense of this application is defined as treating a patient suffering from pain to ameliorate the syndrome by administering a therapeutically effective dose of the co-crystal while at the same time the potential for addiction of tramadol is reduced. In this sense it is understood, that preventing means that the

risk of developing addiction when using the co-crystal is lowered compared to the risk if tramadol is used alone or in combination with celecoxib while having at least the same effect in treating pain

In a further **Aspect B)** the application also relates to a co-crystal of (rac)-tramadol·HCl and celecoxib, or a pharmaceutically acceptable derivative thereof, for treating pain and (while) preventing an addiction to tramadol.

The application thus also relates in this **Aspect B)** to a method for treating pain and (while) preventing an addiction to tramadol, the method comprising administering to the subject a therapeutically effective dose of a co-crystal of (rac)-tramadol·HCl and celecoxib, or a pharmaceutically acceptable derivative thereof.

“Treating pain and preventing an addiction to tramadol” in the sense of this application is defined as treating a patient suffering from pain to ameliorate the syndrome by administering a therapeutically effective dose of the co-crystal while at the same time it is prevented that an addiction to tramadol is developing. In this sense it is understood, that preventing means that the risk of developing addiction when using the co-crystal is lowered compared to the risk if tramadol is used alone or in combination with celecoxib while having at least the same effect in treating pain.

In a further **Aspect C)** the application also relates to a co-crystal of (rac)-tramadol·HCl and celecoxib, or a pharmaceutically acceptable derivative thereof, for treating pain and/while preventing the risk of an addiction to tramadol.

The application thus also relates in this **Aspect C)** to a method for treating pain and/while preventing the risk of an addiction to tramadol, the method comprising administering to the subject a therapeutically effective dose of a co-crystal of (rac)-tramadol·HCl and celecoxib, or a pharmaceutically acceptable derivative thereof.

“Treating pain and/while preventing (lowering) the risk of an addiction to tramadol” in the sense of this application is defined as treating a patient suffering from pain to ameliorate the syndrome by administering a therapeutically effective dose of the co-crystal while at the same time the risk that an addiction to tramadol develops is prevented (or lowered). In this sense it is understood, that preventing (or also lowering) means that the risk of developing addiction when using the co-crystal is lowered compared to the risk if tramadol is used alone or in combination with celecoxib while having at least the same effect in treating pain

In a further **Aspect D)** the application also relates to a co-crystal of (rac)-tramadol·HCl and celecoxib, or a pharmaceutically acceptable derivative thereof, for treating pain in a patient with an addiction to tramadol or the risk of it.

The application thus also relates in this **Aspect D)** to a method for treating pain in a patient with an addiction to tramadol or the risk of it, the method comprising administering to the subject a therapeutically effective dose of a co-crystal of (rac)-tramadol·HCl and celecoxib, or a pharmaceutically acceptable derivative thereof. The application thus also relates in this **Aspect D)** to a method for treating pain in a patient with an addiction to tramadol, the method comprising administering to the subject a therapeutically effective dose of a co-crystal of (rac)-tramadol·HCl and celecoxib, or a pharmaceutically acceptable derivative thereof or to a method for treating pain in a patient at risk of an addiction to tramadol, the method comprising administering to the subject a therapeutically effective dose of a co-crystal of (rac)-tramadol·HCl and celecoxib, or a pharmaceutically acceptable derivative thereof.

“Treating pain in a patient with an addiction to tramadol or the risk of it” in the sense of this application is defined as treating a patient suffering from pain that is at the same time addicted to tramadol (or has the risk of becoming addicted) to ameliorate the syndrome by administering a therapeutically effective dose of the co-crystal. According to the WHO substance addiction is defined as using a substance repeatedly, despite knowing and experiencing harmful effects. Thus, this effect and indication can also be understood as meaning that the risk of developing (or aggravating/worsening) an addiction when using the co-crystal is lowered compared to the risk if tramadol is used alone or in combination with celecoxib while having at least the same effect in treating pain.

In a further **Aspect E)** the application also relates to a co-crystal of (rac)-tramadol·HCl and celecoxib, or a pharmaceutically acceptable derivatives thereof, for treating pain and inhibiting, delaying, reducing or reversing addiction to tramadol.

The application thus also relates in this **Aspect E)** to a method for treating pain and inhibiting, delaying, reducing or reversing addiction to tramadol, the method comprising administering to the subject a therapeutically effective dose of a co-crystal of (rac)-tramadol·HCl and celecoxib, or a pharmaceutically acceptable derivatives thereof.

“Treating pain and inhibiting, delaying, reducing or reversing addiction to tramadol” in the sense of this application is defined as treating a patient suffering from pain to ameliorate the

syndrome by administering a therapeutically effective dose of the co-crystal, while at the same time a (potential) addiction is inhibited, delayed, reduced or reversed (or the risk of a potential addiction is delayed, or reduced). In this sense it is understood, that inhibiting, delaying, reducing or reversing means that the addiction when using the co-crystal is ameliorated compared to the addiction if tramadol is used alone or in combination with celecoxib while having at least the same effect in treating pain (or the risk is lowered, reduced or delayed).

In a further **Aspect F)** the application also relates to a co-crystal of (rac)-tramadol·HCl and celecoxib, or a pharmaceutically acceptable derivatives thereof, for treating pain and reducing the incidence of addiction to tramadol.

The application thus also relates in this **Aspect F)** to a method for treating pain and reducing the incidence of addiction to tramadol, the method comprising administering to the subject a therapeutically effective dose of a co-crystal of (rac)-tramadol·HCl and celecoxib, or a pharmaceutically acceptable derivatives thereof.

“Reducing the incidence of addiction to tramadol” in the sense of this application is defined as treating a patient suffering from pain to ameliorate the syndrome by administering a therapeutically effective dose of the co-crystal while at the same time the incidence of an addiction to tramadol is reduced. In this sense it is understood, that reducing the incidence means that the risk (or the chances of the incident happening) of developing addiction when using the co-crystal is lowered compared to the risk/incidence if tramadol is used alone or in combination with celecoxib while having at least the same effect in treating pain.

In a further **Aspect G)** the application also relates to a co-crystal of (rac)-tramadol·HCl and celecoxib, or a pharmaceutically acceptable derivatives thereof, for treating pain and reducing the likelihood that the treatment will cause an addiction to tramadol.

The application thus also relates in this **Aspect G)** to a method for treating pain and reducing the likelihood that the treatment will cause an addiction to tramadol, the method comprising administering to the subject a therapeutically effective dose of a co-crystal of (rac)-tramadol·HCl and celecoxib, or a pharmaceutically acceptable derivatives thereof.

“Reducing the likelihood that the treatment will cause an addiction to tramadol” in the sense of this application is defined as treating a patient suffering from pain to ameliorate the syndrome by administering a therapeutically effective dose of the co-crystal while at the same time the likelihood that such a treatment is causing an addiction to tramadol is reduced. In this sense it

is understood, that reducing the likelihood means that the risk of developing addiction when using the co-crystal is lowered compared to the risk if tramadol is used alone or in combination with celecoxib while having at least the same effect in treating pain.

“Co-Crystal” as used herein is defined as a crystalline material comprising two or more compounds at ambient temperature (20 to 25°C, preferably 20°C), of which at least two are held together by weak interaction, wherein at least one of the compounds is a co-crystal former. Weak interaction is being defined as an interaction which is neither ionic nor covalent and includes for example: hydrogen bonds, van der Waals forces, and π - π interactions. Solvates of tramadol that do not further comprise a co-crystal former are not co-crystals according to the present invention. The co-crystals may however, include one or more solvate molecules in the crystalline lattice. Just for the sake of clarity the distinction between crystalline salt and a co-crystal has to be stressed here. An API bound to another compound forming a salt by means of ionic interaction can be considered as one “compound” according to the invention, but it cannot be considered as two compounds by itself.

In scientific literature there currently is some discussion on the proper use of the word co-crystal (see for example Desiraju, *Cryst. Eng. Comm.*, 2003, 5(82), 466-467 and Dunitz, *Cryst. Eng. Comm.*, 2003, 5(91), 506). A recent article by Zawarotko (Zwarotko, *Crystal Growth & Design*, Vol. 7, No. 1, 2007, 4-9) gives a definition of co-crystal which is in line with the definition given above and thus also is a definition of “co-crystal” according to this invention. According to this article “a co-crystal is a multiple component crystal in which all components are solid under ambient conditions when in their pure form. These components consist of a target molecule or ion and a molecular co-crystal former(s); when in a co-crystal, they coexist at a molecular level within a single crystal”.

In a preferred embodiment of all **Aspects A) to G)** the application also relates to a co-crystal according to the invention wherein the molecular ratio between the (rac)-tramadol·HCl and celecoxib is 1:1.

E-58425 is a new co-crystal of tramadol HCl and celecoxib in a 1:1 molecular ratio. It appears as an example in WO2011/044962 A1. The overall profile of E-58425, with two relevant active principles for the treatment of pain for oral administration, suggests a unique and useful role in the management of moderate to severe pain.

The co-crystal E-58425 is formulated for oral administration containing as drug substance a co-crystal of racemic tramadol hydrochloride and celecoxib.

In a preferred embodiment of all **Aspects A) to G)** the application also relates to the use of (or a method of treatments using) the co-crystal according to the invention comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, wherein that the co-crystal shows a Powder X-Ray Diffraction pattern with at least one of the peaks [2 θ] selected from the peaks [2 θ] at 7.1, 9.3, 10.2, 10.7, 13.6, 13.9, 14.1, 15.5, 16.1, 16.2, 16.8, 17.5, 18.0, 19.0, 19.5, 19.9, 20.5, 21.2, 21.3, 21.4, 21.8, 22.1, 22.6, 22.7, 23.6, 24.1, 24.4, 25.2, 26.1, 26.6, 26.8, 27.4, 27.9, 28.1, 29.1, 29.9, 30.1, 31.1, 31.3, 31.7, 32.5, 32.8, 34.4, 35.0, 35.8, 36.2 and at 37.2[°].

The 2 θ values are obtained using copper radiation (CuK α 1 1.54060Å). The exact methods of determining this Powder X-Ray Diffraction pattern - which corresponds to the Powder X-Ray Diffraction pattern of E-58425 - can be found in the Example part and the figures of WO2011/044962 A1.

In another preferred embodiment of all **Aspects A) to G)** the application also relates to the use of (or a method of treatments using) the co-crystal according to the invention comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, wherein the co-crystal shows a Powder X-Ray Diffraction pattern with peaks [2 θ] selected from:

- 14.1 and 22.7[°],
- 14.1 and 19.0[°],
- 14.1 and 16.8[°],
- 16.8 and 22.7[°],
- 16.8 and 19.0[°], and
- 19.0 and 22.7[°].

The 2 θ values are obtained using copper radiation (CuK α 1 1.54060Å). The exact methods of determining this Powder X-Ray Diffraction pattern - which corresponds to the Powder X-Ray Diffraction pattern of E-58425 - can be found in the Example part and the figures of WO2011/044962 A1.

In another preferred embodiment of all **Aspects A) to G)** the application also relates to the use of (or a method of treatments using) the co-crystal according to the invention comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, wherein the co-crystal shows a Powder X-Ray Diffraction pattern with peaks [2 θ] selected from:

- 14.1, 16.8 and 22.7[°],
- 14.1, 19.0 and 22.7[°],
- 14.1, 16.8 and 19.0[°], and
- 16.8, 19.0 and 22.7[°].

The 2θ values are obtained using copper radiation ($\text{CuK}\alpha 1\ 1.54060\text{\AA}$). The exact methods of determining this Powder X-Ray Diffraction pattern - which corresponds to the Powder X-Ray Diffraction pattern of E-58425 - can be found in the Example part and the figures of WO2011/044962 A1.

In another preferred embodiment of all **Aspects A) to G)** the application also relates to the use of (or a method of treatments using) the co-crystal according to the invention comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, wherein the co-crystal shows a Powder X-Ray Diffraction pattern with peaks [2θ] at 14.1, 16.8, 19.0 and 22.7[°]. In a further preferred embodiment of this embodiment the co-crystal shows additional peaks [2θ] at 7.1, 19.9 and 20.5[°] and in a further even more preferred embodiment of this preferred embodiment the co-crystal shows additional peaks [2θ] at 13.6, 13.9, 17.5, 18.0, 19.5, 21.2, 21.3, 21.8, 22.6, 23.6, 24.1, 24.4 and 26.1 [°].

The 2θ values are obtained using copper radiation ($\text{CuK}\alpha 1\ 1.54060\text{\AA}$). The exact methods of determining this Powder X-Ray Diffraction pattern - which corresponds to the Powder X-Ray Diffraction pattern of E-58425 - can be found in the Example part and the figures of WO2011/044962 A1.

In another preferred embodiment of all **Aspects A) to G)** the application also relates to the use of (or a method of treatments using) the co-crystal according to the invention comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, wherein the co-crystal shows a Powder X-Ray Diffraction pattern with peaks [2θ] at 7.1, 9.3, 10.2, 10.7, 13.6, 13.9, 14.1, 15.5, 16.1, 16.2, 16.8, 17.5, 18.0, 19.0, 19.5, 19.9, 20.5, 21.2, 21.3, 21.4, 21.8, 22.1, 22.6, 22.7, 23.6, 24.1, 24.4, 25.2, 26.1, 26.6, 26.8, 27.4, 27.9, 28.1, 29.1, 29.9, 30.1, 31.1, 31.3, 31.7, 32.5, 32.8, 34.4, 35.0, 35.8, 36.2 and 37.2[°].

The 2θ values are obtained using copper radiation ($\text{CuK}\alpha 1\ 1.54060\text{\AA}$). The exact methods of determining this Powder X-Ray Diffraction pattern - which corresponds to the Powder X-Ray Diffraction pattern of E-58425 - can be found in the Example part and the figures of WO2011/044962 A1.

In another preferred embodiment of all **Aspects A) to G)** the application also relates to the use of (or a method of treatments using) the co-crystal according to the invention comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, wherein the co-crystal shows a Fourier Transform Infra Red pattern with absorption bands at 3481.6 (m), 3133.5 (m), 2923.0 (m), 2667.7 (m), 1596.0 (m), 1472.4 (m), 1458.0 (m), 1335.1 (m), 1288.7 (m), 1271.8 (m),

1168.7 (s), 1237.3 (m), 1168.7 (s), 1122.6 (s), 1100.9 (m), 1042.2 (m), 976.8 (m), 844.6 (m), 820.1 (m), 786.5 (m) 625.9 (m) cm^{-1} .

The exact methods of determining this Fourier Transform Infra Red pattern - which corresponds to the Fourier Transform Infra Red pattern of E-58425 - can be found in the Example part and the figures of WO2011/044962 A1.

In another preferred embodiment of all **Aspects A) to G)** the application also relates to the use of (or a method of treatments using) the co-crystal according to the invention comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, wherein the co-crystal has an orthorhombic unit cell with the following dimensions:

$$a = 11.0323(7) \text{ \AA}$$

$$b = 18.1095(12) \text{ \AA}$$

$$c = 17.3206(12) \text{ \AA}.$$

The exact methods of determining the nature and dimensions of the co-crystal - which corresponds to the nature and dimensions of E-58425 - can be found in the Example part and the figures of WO2011/044962 A1.

In another preferred embodiment of all **Aspects A) to G)** the application also relates to the use of (or a method of treatments using) the co-crystal according to the invention comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, wherein for the co-crystal the endothermic sharp peak corresponding to the melting point has an onset at 164°C.

The exact methods of determining the onset of the endothermic sharp peak corresponding to the melting point of the co-crystal - which corresponds to the onset of the endothermic sharp peak corresponding to the melting point of E-58425 - can be found in the Example part and the figures of WO2011/044962 A1.

In another preferred embodiment of all **Aspects A) to G)** the application also relates to the use of (or a method of treatments using) the co-crystal according to the invention for the treatment of acute pain, chronic pain, neuropathic pain, nociceptive pain, mild and severe to moderate pain, hyperalgesia, pain related to central sensitization, allodynia or cancer pain, including diabetic neuropathy or diabetic peripheral neuropathy and osteoarthritis, fibromyalgia; rheumatoid arthritis, ankylosing spondylitis, frozen shoulder or sciatica.

In another preferred embodiment of all **Aspects A) to G)** the application also relates to the use of (or a method of treatments using) the co-crystal according to the invention for the treatment of acute and chronic moderate to severe pain, acute moderate to severe pain, acute

moderate pain, acute severe pain, chronic moderate to severe pain, chronic moderate pain, or chronic severe pain.

“Pain” is defined by the International Association for the Study of Pain (IASP) as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage (IASP, Classification of chronic pain, 2nd Edition, IASP Press (2002), 210). Even though pain is always subjective its causes or syndromes can be classified. One classification to denominate subtypes of pain would be to divide the general pain syndrome into the subtypes of acute and chronic pain or – according to the pain intensity - into mild, moderate and severe pain. In other definitions the general pain syndrome is also divided into “nociceptive” (caused by activation of nociceptors), “neuropathic” (caused by damage to or malfunction of the nervous system) and pain related to central sensitization (central pain syndrome).

According to the IASP “allodynia” is defined as “a pain due to a stimulus which does not normally provoke pain” (IASP, Classification of chronic pain, 2nd Edition, IASP Press (2002), 210). Even though the symptoms of allodynia are most likely associated as symptoms of neuropathic pain this is not necessarily the case so that there are symptoms of allodynia not connected to neuropathic pain though rendering allodynia in some areas broader than neuropathic pain.

The IASP further draws the following difference between “allodynia”, “hyperalgesia” and “hyperpathia” (IASP, Classification of chronic pain, 2nd Edition, IASP Press (2002), 212):

Allodynia	Lowered threshold	Stimulus and response mode differ
Hyperalgesia	Increased response	Stimulus and response rate are the same
Hyperpathia	Raised threshold; Increased response	Stimulus and response rate may be the same or different

According to the IASP “neuropathy” is defined as “a primary lesion or dysfunction in the nervous system” (IASP, Classification of chronic pain, 2nd Edition, IASP Press (2002), 211). Neuropathic pain may have central or peripheral origin.

“Sciatica” or “sciatic neuritis is defined herein as a set of symptoms including pain that derive from irritation of the sciatic nerve or its roots,

"Frozen shoulder" or "adhesive capsulitis" is defined herein as a symptom wherein the connective tissue surrounding the shoulder joint or the shoulder capsule itself, is causing chronic pain, becoming inflamed and stiff.

"Ankylosing spondylitis" or "Morbus Bechterew" is a chronic, inflammatory arthritis and autoimmune disease. It mainly affects joints in the spine and the sacroiliac in the pelvis, causing eventual fusion of the spine.

"Pain related to central sensitization" / "central pain syndrome" is defined within this application as a neurological condition caused by damage to or dysfunction of the central nervous system (CNS), which includes the brain, brainstem, and spinal cord. This syndrome can *inter alia* be caused by stroke, multiple sclerosis, tumors, epilepsy, brain or spinal cord trauma, or Parkinson's disease.

"Nociceptive pain" is defined as a type of pain caused by activation of nociceptors. It can be divided into somatic and visceral pain. "Visceral pain" is pain generally originating from the organs, whereas "(deep) somatic pain" originates from ligaments, tendons, bones, blood vessels, fasciae and muscles.

In another preferred embodiment of all **Aspects A) to G)** the application also relates to the use of (or a method of treatments using) the co-crystal according to the invention, wherein the co-crystal is comprised in a pharmaceutical composition also comprising at least a solubility enhancer polymer; wherein the solubility enhancer polymer is selected from polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer or from copovidone, povidone, cyclodextrin, polyethylene glycol and lauroyl macrogol-32 glycerides EP, preferably wherein the solubility enhancer polymer is selected from polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer or other hydrophilic polymers selected from copovidone, or povidone, most preferably wherein the solubility enhancer polymer is copovidone.

Further details of the formulations/pharmaceutical compositions can be found – also referring to E-58425 – in WO2011/151080 A1.

The present invention is illustrated below with the help of the following figures and examples. These illustrations are given solely by way of example and do not limit the invention.

Brief description of the figures:**Figure 1:**

Linear profile of the mean plasma concentrations for tramadol and O-desmethyltramadol after oral administration to healthy male and female subjects of Co-crystal E-58425 (Treatment-1), Ultram[®] (Treatment-2) and Ultram[®] + Celebrex[®] (Treatment-4).

Figure 2:

Abuse Quotient (AQ) for tramadol and its metabolite M1, obtained from Co-crystal E-58425 (Treatment-1) Ultram[®] (Treatment-2) and Ultram[®] + Celebrex[®] (Treatment-4) calculated from the data obtained in a 4-way cross-over study. For opioids, there is high correlation of the C_{max}/T_{max} ratio with pharmacodynamic effects, with higher C_{max}/T_{max} (faster and/or higher absorption) denoting greater abuse potential.

For Co-crystal E-58425, the AQs obtained for tramadol in the 4-way cross-over study were lower than those obtained for Ultram[®] and for Ultram[®] and Celebrex[®] taken concomitantly and these differences were statistically significant, suggesting a lower abuse potential for Co-crystal. No statistically significant differences were observed for Ultram[®] taken alone or in combination with Celebrex[®].

Pharmacokinetic Parameter Definitions

C_{max} Maximum observed plasma concentration

T_{max} Time of maximum observed plasma concentration

AQ Abuse quotient

HPLC High performance liquid chromatography

MS/MS Triple quadrupole mass spectrometry

IS1/ISTD1 Internal standard (tramadol-D6)

IS2/ISTD2 Internal standard (O-desmethyltramadol-D6)

K₂-EDTA Di-potassium ethylene diamine tetraacetic acid

LOQ Lower Limit of Quantitation

M1: O-desmethyltramadol

S.D. Standard Deviation

SE Standard Error

CV Coefficient variation

mg Milligrams

mL Milliliters

ng Nanograms

EXAMPLES

The study was a single center, randomized, single dose, open-label, 4-period, 4-sequence, crossover design in healthy male and female subjects. The following treatments were administered under fasting conditions:

Treatment-1: 2 x 100 mg Co-crystal E-58425 tablets, administered alone

Treatment-2: 2 x 50 mg Tramadol HCl tablets (Ultram®), administered alone

Treatment-3: 1 x 100 mg Celecoxib capsule (Celebrex®), administered alone (data not shown)

Treatment-4: 2 x 50 mg Tramadol tablets (Ultram®) and 1 x 100 mg Celecoxib capsule (Celebrex®), taken concomitantly.

The products were administered to 36 subjects. The wash-out between the periods for each subject was of 7 calendar days.

Table 1. Study Sequences

	Period 1	Period 2	Period 3	Period 4
Sequence 1 (n= 9)	Treatment-1	Treatment-2	Treatment-4	Treatment-3
Sequence 2 (n= 9)	Treatment-2	Treatment-3	Treatment-1	Treatment-4
Sequence 3 (n= 9)	Treatment-3	Treatment-4	Treatment-2	Treatment-1
Sequence 4 (n= 9)	Treatment-4	Treatment-1	Treatment-3	Treatment-2

Handling of Samples

Separate blood samples were obtained for analysis of tramadol / M1 metabolite and for analysis of celecoxib (data not shown). Blood samples for quantification of tramadol and M1 metabolite (Treatment-1, Treatment-2 and Treatment-4) were collected prior to drug administration and at 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36 and 48 hours after drug administration in K₂-EDTA Vacutainers.

As soon as possible following blood collection, samples were centrifuged at a temperature of 4°C nominal and at approximately 1500g for 10 minutes. The plasma obtained was separated into duplicate polypropylene culture tubes. Each tube was labeled in order to identify the drug to be assayed and with a code number that did not reveal formulation identity. The samples were frozen in an upright position and retained in the clinic's freezers at a temperature of -20°C nominal until sent on dry ice to the bioanalytical facility for assay.

Method of Measurement

The experimental human plasma samples were assayed for tramadol and M1 metabolite (O-desmethyltramadol) and also for celecoxib (data not shown) using two different validated bioanalytical methods by HPLC with MS/MS detection.

Sample pre-treatment involved the liquid-liquid extraction of tramadol and O-desmethyltramadol from 0.100 mL of human plasma; tramadol-D6 and O-desmethyltramadol-D6 were used as the internal standards (IS1 and IS2 respectively). The compounds were identified and quantified using HPLC with MS/MS detection over a theoretical concentration range of 2.00 ng/mL to 800.00 ng/mL for tramadol and 0.500 ng/mL to 200.00 ng/mL for O-desmethyltramadol. The concentrations were calculated using peak area ratios and the linearity of the calibration curve was determined using a weighted ($1/x^2$) linear ($y=mx+b$) least squares regression analysis for tramadol and for O-desmethyltramadol.

Pharmacokinetic analysis

Pharmacokinetic parameters were estimated from the individual plasma concentration – time profile for each subject. The main absorption and disposition parameters were obtained using a non-compartmental approach with a log-linear terminal phase assumption. Maximum observed plasma concentration (C_{max}) and the time of maximum observed plasma concentration (T_{max}) were obtained directly from the experimental data. The trapezoidal rule was used to estimate the area under the curve (AUC; data not shown) and the terminal phase was estimated by maximizing the coefficient of determination estimated from the log-linear regression model ($T_{1/2}$; data not shown). The abuse quotient was obtained using the following expression $AQ = C_{max}/T_{max}$.

RESULTS

Table 2.1: Individual and mean values of AQ obtained for tramadol and O-desmethyiltramadol after oral administration of 2 x 100 mg co-crystal E-58425 tablets (Treatment 1) to healthy subjects

Subject	Period	Tramadol			O-desmethyiltramadol		
		C _{max} (ng/mL)	T _{max} (h)	AQ (ng/(mL·h))	C _{max} (ng/mL)	T _{max} (h)	AQ (ng/(mL·h))
1	2	179.23	4.00	44.81	34.93	6.00	5.82
2	1	226.56	8.00	28.32	87.98	8.00	11.00
3	3	224.21	3.00	74.74	53.69	3.00	17.90
4	4	306.70	2.62	117.06	47.51	3.50	13.57
5	4	175.24	3.50	50.07	41.10	4.00	10.28
6	3	105.36	4.00	26.34	71.18	4.00	17.80
7	1	143.59	4.00	35.90	36.17	4.00	9.04
8	2	250.44	2.50	100.18	89.32	3.50	25.52
9	4	207.46	4.00	51.87	37.53	4.00	9.38
10	2	136.31	6.00	22.72	55.51	6.00	9.25
11	1	180.00	3.50	51.43	44.29	4.00	11.07
12	3	194.45	1.75	111.11	50.68	8.00	6.34
13	4	245.13	2.50	98.05	59.24	2.50	23.70
14	3	247.60	3.50	70.74	43.30	6.00	7.22
15	1	318.15	3.53	90.13	71.03	3.53	20.12
16	2	205.79	3.00	68.60	67.64	3.50	19.33
18	1	254.85	3.50	72.81	76.39	3.00	25.46
19	3	200.88	2.50	80.35	49.74	6.00	8.29
20	4	136.40	3.50	38.97	25.88	3.50	7.39
21	1	263.95	3.00	87.98	61.08	4.00	15.27
22	3	256.94	3.00	85.65	39.87	6.00	6.65
23	4	202.08	3.00	67.36	31.18	6.00	5.20
24	2	214.14	2.50	85.66	43.41	3.00	14.47
25	4	103.91	1.25	83.13	65.22	3.50	18.64
26	3	364.28	3.50	104.08	72.02	4.00	18.00
27	2	217.71	4.00	54.43	57.73	6.00	9.62
28	1	162.44	2.50	64.98	45.65	4.00	11.41
29	4	257.07	3.00	85.69	55.55	4.00	13.89
30	2	319.22	3.00	106.41	64.67	6.00	10.78
31	3	166.56	2.50	66.62	39.97	3.00	13.32
33	1	156.84	3.00	52.28	55.41	4.00	13.85
35	2	174.33	3.00	58.11	62.53	3.50	17.87
36	3	272.96	3.00	90.99	61.11	3.50	17.46
n		33	33	33	33	33	33
Mean		214.3	3.3	70.5	54.5	4.4	13.5
Median		207.5	3.0	70.7	55.4	4.0	13.3
SD		62.1	1.2	25.5	15.6	1.4	5.7
CV (%)		29.0	35.4	36.1	28.5	32.3	42.0
SE				4.4			1.0

Subjects 17, 32 and 34 withdrew their consent or were withdrawn from the study

Table 2.2: Individual and mean values of AQ obtained for tramadol and O-desmethyltramadol after oral administration of 2 x 50 mg tramadol HCl tablets (Ultram®), (Treatment 2) to healthy subjects

Subject	Period	Tramadol			O-desmethyltramadol		
		C _{max} (ng/mL)	T _{max} (h)	AQ (ng/(mL·h))	C _{max} (ng/mL)	T _{max} (h)	AQ (ng/(mL·h))
1	4	275.54	1.50	183.69	47.24	3.50	13.50
2	2	285.98	2.50	114.39	93.79	3.00	31.26
3	1	293.07	2.50	117.23	64.62	3.50	18.46
4	3	394.38	1.75	225.36	61.56	2.50	24.62
5	3	273.35	2.00	136.68	60.45	2.00	30.23
6	1	190.51	1.25	152.41	112.97	2.00	56.48
7	2	204.59	3.00	68.20	54.11	3.00	18.04
8	4	298.18	1.75	170.39	123.27	2.50	49.31
9	3	331.21	2.00	165.61	60.50	3.00	20.17
10	4	255.66	1.50	170.44	96.67	1.25	77.33
12	1	273.07	2.00	136.54	69.13	2.50	27.65
13	3	277.09	2.50	110.84	86.80	2.50	34.72
14	1	291.76	2.50	116.70	64.24	2.50	25.70
15	2	372.95	1.25	298.36	78.52	2.53	31.03
16	4	333.42	1.50	222.28	57.13	3.50	16.32
18	2	394.06	2.00	197.03	125.85	2.00	62.92
19	1	300.16	2.00	150.08	85.82	2.00	42.91
20	3	190.23	1.50	126.82	36.27	1.50	24.18
21	2	415.76	2.50	166.30	78.39	2.50	31.35
22	1	334.16	1.50	222.77	64.25	2.00	32.12
23	3	319.62	2.50	127.85	53.55	3.50	15.30
24	4	321.71	1.25	257.37	72.99	2.50	29.19
25	3	174.58	1.75	99.76	115.95	1.50	77.30
26	1	378.07	2.50	151.23	102.42	3.00	34.14
27	4	292.50	2.00	146.25	68.97	6.00	11.50
28	2	229.64	2.00	114.82	58.07	2.00	29.04
29	3	395.06	2.00	197.53	81.57	3.00	27.19
30	4	465.87	1.50	310.58	100.31	1.50	66.88
31	1	218.09	1.50	145.39	62.89	1.50	41.92
33	2	324.94	0.75	433.25	96.33	1.25	77.06
35	4	285.83	1.75	163.33	102.18	2.00	51.09
36	1	377.10	2.50	150.84	74.45	2.50	29.78
n		32	32	32	32	32	32
Mean		305.3	1.9	173.4	78.5	2.5	36.2
Median		295.6	2.0	151.8	73.7	2.5	30.6
SD		70.6	0.5	72.3	22.9	0.9	19.1
CV (%)		23.1	26.6	41.7	29.2	36.9	52.6
SE				12.8			3.4

Subjects 11, 17, 32 and 34 withdrew their consent or were withdrawn from the study

Table 2.3: Individual and mean values of AQ obtained for tramadol and O-desmethyiltramadol after oral administration of 2 x 50 mg tramadol HCl tablets (Ultram®) and 1 x 100 mg celecoxib capsule (Celebrex®), (Treatment 4) to healthy subjects

Subject	Period	Tramadol			O-desmethyiltramadol		
		C _{max} (ng/mL)	T _{max} (h)	AQ (ng/(mL·h))	C _{max} (ng/mL)	T _{max} (h)	AQ (ng/(mL·h))
1	1	267.76	1.25	214.21	52.60	3.00	17.53
2	3	331.19	2.00	165.60	90.06	3.50	25.73
3	4	276.09	2.50	110.44	75.05	3.00	25.02
4	2	373.85	2.00	186.93	62.55	2.50	25.02
5	2	296.43	2.00	148.22	68.77	2.00	34.38
6	4	193.76	2.00	96.88	112.69	2.00	56.35
7	3	250.01	2.00	125.01	57.33	2.50	22.93
8	1	350.74	1.50	233.83	125.29	1.50	83.52
9	2	287.00	1.50	191.33	70.88	2.00	35.44
10	1	221.30	2.50	88.52	89.66	1.25	71.72
11	3	266.67	2.00	133.34	71.36	2.00	35.68
13	2	329.98	1.50	219.99	71.82	1.50	47.88
14	4	356.89	1.50	237.93	47.68	2.00	23.84
15	3	362.70	1.75	207.26	76.98	2.50	30.79
16	1	277.99	2.00	139.00	84.30	2.50	33.72
18	3	378.74	1.50	252.49	135.81	2.00	67.90
19	4	340.45	1.00	340.45	74.15	2.50	29.66
20	2	183.99	1.50	122.66	36.56	1.75	20.89
21	3	371.22	3.00	123.74	69.61	4.00	17.40
22	4	392.02	1.50	261.35	54.10	2.50	21.64
23	2	346.39	2.00	173.20	53.63	3.00	17.88
24	1	304.72	2.00	152.36	79.84	2.50	31.93
25	2	194.35	1.25	155.48	112.05	1.50	74.70
26	4	465.57	2.00	232.79	96.57	2.50	38.63
27	1	323.08	1.50	215.39	74.52	3.00	24.84
28	3	347.87	1.28	271.77	65.66	8.00	8.21
29	2	320.68	2.50	128.27	72.37	2.50	28.95
30	1	438.45	1.25	350.76	103.69	1.75	59.25
31	4	211.89	3.00	70.63	58.13	3.00	19.38
33	3	313.18	1.00	313.18	86.13	1.75	49.22
35	1	325.70	1.75	186.11	106.36	1.75	60.78
36	4	294.15	6.00	49.03	66.99	6.00	11.17
n		32	32	32	32	32	32
Mean		312.3	1.9	184.3	78.2	2.6	36.0
Median		321.9	1.9	179.7	73.3	2.5	30.2
SD		67.7	0.9	75.0	22.9	1.3	19.7
CV (%)		21.7	46.3	40.7	29.3	50.8	54.6
SE				13.3			3.5

Subjects 12, 17, 32 and 34 withdrew their consent or were withdrawn from the study

Table 3: Summary of AQ obtained for tramadol and O-desmethytramadol (M1) after oral administration of co-crystal E-58425 tablets, 2 x 50 mg tramadol HCl tablets (Ultram®) and 2 x 50 mg tramadol HCl tablets (Ultram®), and 1 x 100 mg celecoxib capsule (Celebrex®) to healthy subjects

AQ	Co-crystal E-58425		Ultram ^R		Ultram ^R + Celebrex ^R	
	Mean	SE	Mean	SE	Mean	SE
Tramadol	70.5	4.4	173.4	12.8	184.3	13.3
M1	13.5	1.0	36.2	3.4	36.0	3.5

EMBODIMENTS:

- E1) A co-crystal of (rac)-tramadol·HCl and celecoxib, or a pharmaceutically acceptable derivatives thereof, for treating pain while reducing the abuse liability of (the) tramadol.
- E2) The co-crystal for use according to embodiment E1), wherein the molecular ratio between the (rac)-tramadol·HCl and celecoxib is 1:1.
- E3) The co-crystal for use according to any one of embodiments E1) or E2) comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, characterized in that the co-crystal shows a Powder X-Ray Diffraction pattern with at least one of the peaks [2θ] selected from 7.1, 9.3, 10.2, 10.7, 13.6, 13.9, 14.1, 15.5, 16.1, 16.2, 16.8, 17.5, 18.0, 19.0, 19.5, 19.9, 20.5, 21.2, 21.3, 21.4, 21.8, 22.1, 22.6, 22.7, 23.6, 24.1, 24.4, 25.2, 26.1, 26.6, 26.8, 27.4, 27.9, 28.1, 29.1, 29.9, 30.1, 31.1, 31.3, 31.7, 32.5, 32.8, 34.4, 35.0, 35.8, 36.2 and 37.2[°], with the 2θ values being obtained using copper radiation (CuKα1 1.54060Å).
- E4) The co-crystal for use according to any one of embodiments E2) or E3), characterized in that the co-crystal shows a Powder X-Ray Diffraction pattern with peaks [2θ] at:
- 14.1 and 22.7[°],
 - 14.1 and 19.0[°],
 - 14.1 and 16.8[°],
 - 16.8 and 22.7[°],
 - 16.8 and 19.0[°], or
 - 19.0 and 22.7[°],
- with the 2θ values being obtained using copper radiation (CuKα1 1.54060Å).
- E5) The co-crystal for use according to any one of embodiments E2) to E4), characterized in that the co-crystal shows a Powder X-Ray Diffraction pattern with peaks [2θ] at:

- 14.1, 16.8 and 22.7[°],
- 14.1, 19.0 and 22.7[°],
- 14.1, 16.8 and 19.0[°], or
- 16.8, 19.0 and 22.7[°],

with the 2θ values being obtained using copper radiation (CuK α 1 1.54060Å).

- E6) The co-crystal for use according to any one of embodiments E2) to E5), characterized in that the co-crystal shows a Powder X-Ray Diffraction pattern with peaks [2θ] at 14.1, 16.8, 19.0 and 22.7[°], with the 2θ values being obtained using copper radiation (CuK α 1 1.54060Å).
- E7) The co-crystal for use according to embodiment E6), characterized in that the co-crystal shows additional peaks [2θ] at 7.1, 19.9 and 20.5[°].
- E8) The co-crystal for use according to embodiment E7), characterized in that the co-crystal shows additional peaks [2θ] at 13.6, 13.9, 17.5, 18.0, 19.5, 21.2, 21.3, 21.8, 22.6, 23.6, 24.1, 24.4 and 26.1 [°].
- E9) The co-crystal for use according to any one of embodiments E1) to E8) comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, characterized in that the co-crystal shows a Powder X-Ray Diffraction pattern with peaks [2θ] at 7.1, 9.3, 10.2, 10.7, 13.6, 13.9, 14.1, 15.5, 16.1, 16.2, 16.8, 17.5, 18.0, 19.0, 19.5, 19.9, 20.5, 21.2, 21.3, 21.4, 21.8, 22.1, 22.6, 22.7, 23.6, 24.1, 24.4, 25.2, 26.1, 26.6, 26.8, 27.4, 27.9, 28.1, 29.1, 29.9, 30.1, 31.1, 31.3, 31.7, 32.5, 32.8, 34.4, 35.0, 35.8, 36.2 and 37.2[°], with the 2θ values being obtained using copper radiation (CuK α 1 1.54060Å).
- E10) The co-crystal for use according to any one of embodiments E1) to E9) comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, characterized in that the co-crystal shows a Fourier Transform Infra Red pattern with absorption bands at 3481.6 (m), 3133.5 (m), 2923.0 (m), 2667.7 (m), 1596.0 (m), 1472.4 (m), 1458.0 (m), 1335.1 (m), 1288.7 (m), 1271.8 (m), 1168.7 (s), 1237.3 (m), 1168.7 (s), 1122.6 (s), 1100.9 (m), 1042.2 (m), 976.8 (m), 844.6 (m), 820.1 (m), 786.5 (m) 625.9 (m) cm⁻¹.
- E11) The co-crystal for use according to any one of embodiments E1) to E10) comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, characterized in that the co-crystal has an orthorhombic unit cell with the following dimensions:

$$\begin{aligned}a &= 11.0323(7) \text{ \AA} \\b &= 18.1095(12) \text{ \AA} \\c &= 17.3206(12) \text{ \AA}.\end{aligned}$$

- E12) The co-crystal for use according to any one of embodiments E1) to E11) comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, characterized in that for the co-crystal the endothermic sharp peak corresponding to the melting point has an onset at 164°C.
- E13) The co-crystal for use according to any one of embodiments E1) to E12), for the treatment of acute pain, chronic pain, neuropathic pain, nociceptive pain, mild and severe to moderate pain, hyperalgesia, pain related to central sensitization, allodynia or cancer pain, including diabetic neuropathy or diabetic peripheral neuropathy and osteoarthritis, fibromyalgia; rheumatoid arthritis, ankylosing spondylitis, frozen shoulder or sciatica.
- E14) The co-crystal for use according to any one of embodiments E1) to E13), for the treatment of acute and chronic moderate to severe pain, acute moderate to severe pain, acute moderate pain, acute severe pain, chronic moderate to severe pain, chronic moderate pain, or chronic severe pain.
- E15) The co-crystal for use according to to any one of embodiments E1) to E14) wherein the co-crystal is comprised in a pharmaceutical composition also comprising at least a solubility enhancer polymer; wherein the solubility enhancer polymer is selected from polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer or from copovidone, povidone, cyclodextrin, polyethylene glycol and lauroyl macrogol-32 glycerides EP, preferably wherein the solubility enhancer polymer is selected from polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer or other hydrophilic polymers selected from copovidone, or povidone, most preferably wherein the solubility enhancer polymer is copovidone.
- E21) A co-crystal of (rac)-tramadol·HCl and celecoxib, or a pharmaceutically acceptable derivatives thereof, for treating pain and preventing an addiction to tramadol.
- E22) The co-crystal for use according to embodiment E21), wherein the molecular ratio between the (rac)-tramadol·HCl and celecoxib is 1:1.

- E23) The co-crystal for use according to any one of embodiments E21) or E22) comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, characterized in that the co-crystal shows a Powder X-Ray Diffraction pattern with at least one of the peaks [2 θ] selected from 7.1, 9.3, 10.2, 10.7, 13.6, 13.9, 14.1, 15.5, 16.1, 16.2, 16.8, 17.5, 18.0, 19.0, 19.5, 19.9, 20.5, 21.2, 21.3, 21.4, 21.8, 22.1, 22.6, 22.7, 23.6, 24.1, 24.4, 25.2, 26.1, 26.6, 26.8, 27.4, 27.9, 28.1, 29.1, 29.9, 30.1, 31.1, 31.3, 31.7, 32.5, 32.8, 34.4, 35.0, 35.8, 36.2 and 37.2[°], with the 2 θ values being obtained using copper radiation (CuK α 1 1.54060Å).
- E24) The co-crystal for use according to any one of embodiments E22) or E23), characterized in that the co-crystal shows a Powder X-Ray Diffraction pattern with peaks [2 θ] at:
- 14.1 and 22.7[°],
 - 14.1 and 19.0[°],
 - 14.1 and 16.8[°],
 - 16.8 and 22.7[°],
 - 16.8 and 19.0[°], or
 - 19.0 and 22.7[°],
- with the 2 θ values being obtained using copper radiation (CuK α 1 1.54060Å).
- E25) The co-crystal for use according to any one of embodiments E22) to E24), characterized in that the co-crystal shows a Powder X-Ray Diffraction pattern with peaks [2 θ] at:
- 14.1, 16.8 and 22.7[°],
 - 14.1, 19.0 and 22.7[°],
 - 14.1, 16.8 and 19.0[°], or
 - 16.8, 19.0 and 22.7[°],
- with the 2 θ values being obtained using copper radiation (CuK α 1 1.54060Å).
- E26) The co-crystal for use according to any one of embodiments E22) to E25), characterized in that the co-crystal shows a Powder X-Ray Diffraction pattern with peaks [2 θ] at 14.1, 16.8, 19.0 and 22.7[°], with the 2 θ values being obtained using copper radiation (CuK α 1 1.54060Å).
- E27) The co-crystal for use according to embodiment E26), characterized in that the co-crystal shows additional peaks [2 θ] at 7.1, 19.9 and 20.5[°].

- E28) The co-crystal for use according to embodiment E27), characterized in that the co-crystal shows additional peaks [2 θ] at 13.6, 13.9, 17.5, 18.0, 19.5, 21.2, 21.3, 21.8, 22.6, 23.6, 24.1, 24.4 and 26.1 [°].
- E29) The co-crystal for use according to any one of embodiments E21) to E28) comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, characterized in that the co-crystal shows a Powder X-Ray Diffraction pattern with peaks [2 θ] at 7.1, 9.3, 10.2, 10.7, 13.6, 13.9, 14.1, 15.5, 16.1, 16.2, 16.8, 17.5, 18.0, 19.0, 19.5, 19.9, 20.5, 21.2, 21.3, 21.4, 21.8, 22.1, 22.6, 22.7, 23.6, 24.1, 24.4, 25.2, 26.1, 26.6, 26.8, 27.4, 27.9, 28.1, 29.1, 29.9, 30.1, 31.1, 31.3, 31.7, 32.5, 32.8, 34.4, 35.0, 35.8, 36.2 and 37.2[°], with the 2 θ values being obtained using copper radiation (CuK α 1 1.54060Å).
- E30) The co-crystal for use according to any one of embodiments E21) to E29) comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, characterized in that the co-crystal shows a Fourier Transform Infra Red pattern with absorption bands at 3481.6 (m), 3133.5 (m), 2923.0 (m), 2667.7 (m), 1596.0 (m), 1472.4 (m), 1458.0 (m), 1335.1 (m), 1288.7 (m), 1271.8 (m), 1168.7 (s), 1237.3 (m), 1168.7 (s), 1122.6 (s), 1100.9 (m), 1042.2 (m), 976.8 (m), 844.6 (m), 820.1 (m), 786.5 (m) 625.9 (m) cm⁻¹.
- E31) The co-crystal for use according to any one of embodiments E21) to E30) comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, characterized in that the co-crystal has an orthorhombic unit cell with the following dimensions:
- $a = 11.0323(7) \text{ \AA}$
 $b = 18.1095(12) \text{ \AA}$
 $c = 17.3206(12) \text{ \AA}$.
- E32) The co-crystal for use according to any one of embodiments E21) to E31) comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, characterized in that for the co-crystal the endothermic sharp peak corresponding to the melting point has an onset at 164°C.
- E33) The co-crystal for use according to any one of embodiments E21) to E32), for the treatment of acute pain, chronic pain, neuropathic pain, nociceptive pain, mild and severe to moderate pain, hyperalgesia, pain related to central sensitization, allodynia or cancer pain, including diabetic neuropathy or diabetic peripheral neuropathy and

osteoarthritis, fibromyalgia; rheumatoid arthritis, ankylosing spondylitis, frozen shoulder or sciatica.

- E34) The co-crystal for use according to any one of embodiments E21) to E33), for the treatment of acute and chronic moderate to severe pain, acute moderate to severe pain, acute moderate pain, acute severe pain, chronic moderate to severe pain, chronic moderate pain, or chronic severe pain.
- E35) The co-crystal for use according to any one of embodiments E21) to E34) wherein the co-crystal is comprised in a pharmaceutical composition also comprising at least a solubility enhancer polymer; wherein the solubility enhancer polymer is selected from polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer or from copovidone, povidone, cyclodextrin, polyethylene glycol and lauroyl macrogol-32 glycerides EP, preferably wherein the solubility enhancer polymer is selected from polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer or other hydrophilic polymers selected from copovidone, or povidone, most preferably wherein the solubility enhancer polymer is copovidone.
- E41) A co-crystal of (rac)-tramadol·HCl and celecoxib, or a pharmaceutically acceptable derivatives thereof, for treating pain, preventing the risk of an addiction to tramadol.
- E42) The co-crystal for use according to embodiment E41), wherein the molecular ratio between the (rac)-tramadol·HCl and celecoxib is 1:1.
- E43) The co-crystal for use according to any one of embodiments E41) or E42) comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, characterized in that the co-crystal shows a Powder X-Ray Diffraction pattern with at least one of the peaks [2 θ] selected from 7.1, 9.3, 10.2, 10.7, 13.6, 13.9, 14.1, 15.5, 16.1, 16.2, 16.8, 17.5, 18.0, 19.0, 19.5, 19.9, 20.5, 21.2, 21.3, 21.4, 21.8, 22.1, 22.6, 22.7, 23.6, 24.1, 24.4, 25.2, 26.1, 26.6, 26.8, 27.4, 27.9, 28.1, 29.1, 29.9, 30.1, 31.1, 31.3, 31.7, 32.5, 32.8, 34.4, 35.0, 35.8, 36.2 and 37.2[°], with the 2 θ values being obtained using copper radiation (CuK α 1 1.54060Å).
- E44) The co-crystal for use according to any one of embodiments E42) or E43), characterized in that the co-crystal shows a Powder X-Ray Diffraction pattern with peaks [2 θ] at:
- 14.1 and 22.7[°],

- 14.1 and 19.0[°],
- 14.1 and 16.8[°],
- 16.8 and 22.7[°],
- 16.8 and 19.0[°], or
- 19.0 and 22.7[°],

with the 2 θ values being obtained using copper radiation (CuK α 1 1.54060Å).

E45) The co-crystal for use according to any one of embodiments E42) to E44), characterized in that the co-crystal shows a Powder X-Ray Diffraction pattern with peaks [2 θ] with the 2 θ values being obtained using copper radiation (CuK α 1 1.54060Å) at:

- 14.1, 16.8 and 22.7[°],
- 14.1, 19.0 and 22.7[°],
- 14.1, 16.8 and 19.0[°], or
- 16.8, 19.0 and 22.7[°],

with the 2 θ values being obtained using copper radiation (CuK α 1 1.54060Å).

E46) The co-crystal for use according to any one of embodiments E42) to E45), characterized in that the co-crystal shows a Powder X-Ray Diffraction pattern with peaks [2 θ] at 14.1, 16.8, 19.0 and 22.7[°], with the 2 θ values being obtained using copper radiation (CuK α 1 1.54060Å).

E47) The co-crystal for use according to embodiment E46), characterized in that the co-crystal shows additional peaks [2 θ] at 7.1, 19.9 and 20.5[°].

E48) The co-crystal for use according to embodiment E47), characterized in that the co-crystal shows additional peaks [2 θ] at 13.6, 13.9, 17.5, 18.0, 19.5, 21.2, 21.3, 21.8, 22.6, 23.6, 24.1, 24.4 and 26.1 [°].

E49) The co-crystal for use according to any one of embodiments E41) to E48) comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, characterized in that the co-crystal shows a Powder X-Ray Diffraction pattern with peaks [2 θ] at 7.1, 9.3, 10.2, 10.7, 13.6, 13.9, 14.1, 15.5, 16.1, 16.2, 16.8, 17.5, 18.0, 19.0, 19.5, 19.9, 20.5, 21.2, 21.3, 21.4, 21.8, 22.1, 22.6, 22.7, 23.6, 24.1, 24.4, 25.2, 26.1, 26.6, 26.8, 27.4, 27.9, 28.1, 29.1, 29.9, 30.1, 31.1, 31.3, 31.7, 32.5, 32.8, 34.4, 35.0, 35.8, 36.2 and 37.2[°], with the 2 θ values being obtained using copper radiation (CuK α 1 1.54060Å).

- E50) The co-crystal for use according to any one of embodiments E41) to E49) comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, characterized in that the co-crystal shows a Fourier Transform Infra Red pattern with absorption bands at 3481.6 (m), 3133.5 (m), 2923.0 (m), 2667.7 (m), 1596.0 (m), 1472.4 (m), 1458.0 (m), 1335.1 (m), 1288.7 (m), 1271.8 (m), 1168.7 (s), 1237.3 (m), 1168.7 (s), 1122.6 (s), 1100.9 (m), 1042.2 (m), 976.8 (m), 844.6 (m), 820.1 (m), 786.5 (m) 625.9 (m) cm⁻¹.
- E51) The co-crystal for use according to any one of embodiments E41) to E50) comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, characterized in that the co-crystal has an orthorhombic unit cell with the following dimensions:
- $a = 11.0323(7) \text{ \AA}$
 $b = 18.1095(12) \text{ \AA}$
 $c = 17.3206(12) \text{ \AA}$.
- E52) The co-crystal for use according to any one of embodiments E41) to E51) comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, characterized in that for the co-crystal the endothermic sharp peak corresponding to the melting point has an onset at 164°C.
- E53) The co-crystal for use according to any one of embodiments E41) to E52), for the treatment of acute pain, chronic pain, neuropathic pain, nociceptive pain, mild and severe to moderate pain, hyperalgesia, pain related to central sensitization, allodynia or cancer pain, including diabetic neuropathy or diabetic peripheral neuropathy and osteoarthritis, fibromyalgia; rheumatoid arthritis, ankylosing spondylitis, frozen shoulder or sciatica.
- E54) The co-crystal for use according to any one of embodiments E41) to E53), for the treatment of acute and chronic moderate to severe pain, acute moderate to severe pain, acute moderate pain, acute severe pain, chronic moderate to severe pain, chronic moderate pain, or chronic severe pain.
- E55) The co-crystal for use according to to any one of embodiments E41) to E54) wherein the co-crystal is comprised in a pharmaceutical composition also comprising at least a solubility enhancer polymer; wherein the solubility enhancer polymer is selected from polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer or from copovidone, povidone, cyclodextrin, polyethylene glycol and lauroyl macrogol-

32 glycerides EP, preferably wherein the solubility enhancer polymer is selected from polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer or other hydrophilic polymers selected from copovidone, or povidone, most preferably wherein the solubility enhancer polymer is copovidone.

- E61) A co-crystal of (rac)-tramadol·HCl and celecoxib, or a pharmaceutically acceptable derivatives thereof, for treating pain in a patient with an addiction to tramadol or the risk of it.
- E62) The co-crystal for use according to embodiment E61), wherein the molecular ratio between the (rac)-tramadol·HCl and celecoxib is 1:1.
- E63) The co-crystal for use according to any one of embodiments E61) or E62) comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, characterized in that the co-crystal shows a Powder X-Ray Diffraction pattern with at least one of the peaks [2 θ] selected from 7.1, 9.3, 10.2, 10.7, 13.6, 13.9, 14.1, 15.5, 16.1, 16.2, 16.8, 17.5, 18.0, 19.0, 19.5, 19.9, 20.5, 21.2, 21.3, 21.4, 21.8, 22.1, 22.6, 22.7, 23.6, 24.1, 24.4, 25.2, 26.1, 26.6, 26.8, 27.4, 27.9, 28.1, 29.1, 29.9, 30.1, 31.1, 31.3, 31.7, 32.5, 32.8, 34.4, 35.0, 35.8, 36.2 and 37.2[°], with the 2 θ values being obtained using copper radiation (CuK α 1 1.54060Å).
- E64) The co-crystal for use according to any one of embodiments E62) or E63), characterized in that the co-crystal shows a Powder X-Ray Diffraction pattern with peaks [2 θ] at:
- 14.1 and 22.7[°],
 - 14.1 and 19.0[°],
 - 14.1 and 16.8[°],
 - 16.8 and 22.7[°],
 - 16.8 and 19.0[°], or
 - 19.0 and 22.7[°],
- with the 2 θ values being obtained using copper radiation (CuK α 1 1.54060Å).
- E65) The co-crystal for use according to any one of embodiments E62) to E64), characterized in that the co-crystal shows a Powder X-Ray Diffraction pattern with peaks [2 θ] at:
- 14.1, 16.8 and 22.7[°],
 - 14.1, 19.0 and 22.7[°],

- 14.1, 16.8 and 19.0[°], or
- 16.8, 19.0 and 22.7[°],

with the 2θ values being obtained using copper radiation ($\text{CuK}\alpha 1.54060\text{\AA}$).

- E66) The co-crystal for use according to any one of embodiments E62) to E65), characterized in that the co-crystal shows a Powder X-Ray Diffraction pattern with peaks $[2\theta]$ at 14.1, 16.8, 19.0 and 22.7[°], with the 2θ values being obtained using copper radiation ($\text{CuK}\alpha 1.54060\text{\AA}$).
- E67) The co-crystal for use according to embodiment E66), characterized in that the co-crystal shows additional peaks $[2\theta]$ at 7.1, 19.9 and 20.5[°].
- E68) The co-crystal for use according to embodiment E67), characterized in that the co-crystal shows additional peaks $[2\theta]$ at 13.6, 13.9, 17.5, 18.0, 19.5, 21.2, 21.3, 21.8, 22.6, 23.6, 24.1, 24.4 and 26.1 [°].
- E69) The co-crystal for use according to any one of embodiments E61) to E68) comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, characterized in that the co-crystal shows a Powder X-Ray Diffraction pattern with peaks $[2\theta]$ at 7.1, 9.3, 10.2, 10.7, 13.6, 13.9, 14.1, 15.5, 16.1, 16.2, 16.8, 17.5, 18.0, 19.0, 19.5, 19.9, 20.5, 21.2, 21.3, 21.4, 21.8, 22.1, 22.6, 22.7, 23.6, 24.1, 24.4, 25.2, 26.1, 26.6, 26.8, 27.4, 27.9, 28.1, 29.1, 29.9, 30.1, 31.1, 31.3, 31.7, 32.5, 32.8, 34.4, 35.0, 35.8, 36.2 and 37.2[°], with the 2θ values being obtained using copper radiation ($\text{CuK}\alpha 1.54060\text{\AA}$).
- E70) The co-crystal for use according to any one of embodiments E61) to E69) comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, characterized in that the co-crystal shows a Fourier Transform Infra Red pattern with absorption bands at 3481.6 (m), 3133.5 (m), 2923.0 (m), 2667.7 (m), 1596.0 (m), 1472.4 (m), 1458.0 (m), 1335.1 (m), 1288.7 (m), 1271.8 (m), 1168.7 (s), 1237.3 (m), 1168.7 (s), 1122.6 (s), 1100.9 (m), 1042.2 (m), 976.8 (m), 844.6 (m), 820.1 (m), 786.5 (m) 625.9 (m) cm^{-1} .
- E71) The co-crystal for use according to any one of embodiments E61) to E70) comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, characterized in that the co-crystal has an orthorhombic unit cell with the following dimensions:

$$a = 11.0323(7) \text{ \AA}$$

$$b = 18.1095(12) \text{ \AA}$$

$$c = 17.3206(12) \text{ \AA}.$$

- E72) The co-crystal for use according to any one of embodiments E61) to E71) comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, characterized in that for the co-crystal the endothermic sharp peak corresponding to the melting point has an onset at 164°C.
- E73) The co-crystal for use according to any one of embodiments E61) to E72), for the treatment of acute pain, chronic pain, neuropathic pain, nociceptive pain, mild and severe to moderate pain, hyperalgesia, pain related to central sensitization, allodynia or cancer pain, including diabetic neuropathy or diabetic peripheral neuropathy and osteoarthritis, fibromyalgia; rheumatoid arthritis, ankylosing spondylitis, frozen shoulder or sciatica.
- E74) The co-crystal for use according to any one of embodiments E61) to E73), for the treatment of acute and chronic moderate to severe pain, acute moderate to severe pain, acute moderate pain, acute severe pain, chronic moderate to severe pain, chronic moderate pain, or chronic severe pain.
- E75) The co-crystal for use according to any one of embodiments E61) to E74) wherein the co-crystal is comprised in a pharmaceutical composition also comprising at least a solubility enhancer polymer; wherein the solubility enhancer polymer is selected from polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer or from copovidone, povidone, cyclodextrin, polyethylene glycol and lauroyl macrogol-32 glycerides EP, preferably wherein the solubility enhancer polymer is selected from polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer or other hydrophilic polymers selected from copovidone, or povidone, most preferably wherein the solubility enhancer polymer is copovidone.
- E81) A co-crystal of (rac)-tramadol·HCl and celecoxib, or a pharmaceutically acceptable derivatives thereof, for treating pain and inhibiting, delaying, reducing or reversing addiction to tramadol.
- E82) The co-crystal for use according to embodiment E81), wherein the molecular ratio between the (rac)-tramadol·HCl and celecoxib is 1:1.

- E83) The co-crystal for use according to any one of embodiments E81) or E82) comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, characterized in that the co-crystal shows a Powder X-Ray Diffraction pattern with at least one of the peaks [2 θ] selected from 7.1, 9.3, 10.2, 10.7, 13.6, 13.9, 14.1, 15.5, 16.1, 16.2, 16.8, 17.5, 18.0, 19.0, 19.5, 19.9, 20.5, 21.2, 21.3, 21.4, 21.8, 22.1, 22.6, 22.7, 23.6, 24.1, 24.4, 25.2, 26.1, 26.6, 26.8, 27.4, 27.9, 28.1, 29.1, 29.9, 30.1, 31.1, 31.3, 31.7, 32.5, 32.8, 34.4, 35.0, 35.8, 36.2 and 37.2[°], with the 2 θ values being obtained using copper radiation (CuK α 1 1.54060Å).
- E84) The co-crystal for use according to any one of embodiments E82) or E83), characterized in that the co-crystal shows a Powder X-Ray Diffraction pattern with peaks [2 θ] at:
- 14.1 and 22.7[°],
 - 14.1 and 19.0[°],
 - 14.1 and 16.8[°],
 - 16.8 and 22.7[°],
 - 16.8 and 19.0[°], or
 - 19.0 and 22.7[°],
- with the 2 θ values being obtained using copper radiation (CuK α 1 1.54060Å).
- E85) The co-crystal for use according to any one of embodiments E82) to E84), characterized in that the co-crystal shows a Powder X-Ray Diffraction pattern with peaks [2 θ] at:
- 14.1, 16.8 and 22.7[°],
 - 14.1, 19.0 and 22.7[°],
 - 14.1, 16.8 and 19.0[°], or
 - 16.8, 19.0 and 22.7[°],
- with the 2 θ values being obtained using copper radiation (CuK α 1 1.54060Å).
- E86) The co-crystal for use according to any one of embodiments E82) to E85), characterized in that the co-crystal shows a Powder X-Ray Diffraction pattern with peaks [2 θ] at 14.1, 16.8, 19.0 and 22.7[°], with the 2 θ values being obtained using copper radiation (CuK α 1 1.54060Å).
- E87) The co-crystal for use according to embodiment E86), characterized in that the co-crystal shows additional peaks [2 θ] at 7.1, 19.9 and 20.5[°].

- E88) The co-crystal for use according to embodiment E87), characterized in that the co-crystal shows additional peaks [2 θ] at 13.6, 13.9, 17.5, 18.0, 19.5, 21.2, 21.3, 21.8, 22.6, 23.6, 24.1, 24.4 and 26.1 [°].
- E89) The co-crystal for use according to any one of embodiments E81) to E88) comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, characterized in that the co-crystal shows a Powder X-Ray Diffraction pattern with peaks [2 θ] at 7.1, 9.3, 10.2, 10.7, 13.6, 13.9, 14.1, 15.5, 16.1, 16.2, 16.8, 17.5, 18.0, 19.0, 19.5, 19.9, 20.5, 21.2, 21.3, 21.4, 21.8, 22.1, 22.6, 22.7, 23.6, 24.1, 24.4, 25.2, 26.1, 26.6, 26.8, 27.4, 27.9, 28.1, 29.1, 29.9, 30.1, 31.1, 31.3, 31.7, 32.5, 32.8, 34.4, 35.0, 35.8, 36.2 and 37.2[°], with the 2 θ values being obtained using copper radiation (CuK α 1 1.54060Å).
- E90) The co-crystal for use according to any one of embodiments E81) to E89) comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, characterized in that the co-crystal shows a Fourier Transform Infra Red pattern with absorption bands at 3481.6 (m), 3133.5 (m), 2923.0 (m), 2667.7 (m), 1596.0 (m), 1472.4 (m), 1458.0 (m), 1335.1 (m), 1288.7 (m), 1271.8 (m), 1168.7 (s), 1237.3 (m), 1168.7 (s), 1122.6 (s), 1100.9 (m), 1042.2 (m), 976.8 (m), 844.6 (m), 820.1 (m), 786.5 (m) 625.9 (m) cm⁻¹.
- E91) The co-crystal for use according to any one of embodiments E81) to E90) comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, characterized in that the co-crystal has an orthorhombic unit cell with the following dimensions:
- $a = 11.0323(7) \text{ \AA}$
 $b = 18.1095(12) \text{ \AA}$
 $c = 17.3206(12) \text{ \AA}$.
- E92) The co-crystal for use according to any one of embodiments E81) to E91) comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, characterized in that for the co-crystal the endothermic sharp peak corresponding to the melting point has an onset at 164°C.
- E93) The co-crystal for use according to any one of embodiments E81) to E92), for the treatment of acute pain, chronic pain, neuropathic pain, nociceptive pain, mild and severe to moderate pain, hyperalgesia, pain related to central sensitization, allodynia or cancer pain, including diabetic neuropathy or diabetic peripheral neuropathy and

osteoarthritis, fibromyalgia; rheumatoid arthritis, ankylosing spondylitis, frozen shoulder or sciatica.

- E94) The co-crystal for use according to any one of embodiments E81) to E93), for the treatment of acute and chronic moderate to severe pain, acute moderate to severe pain, acute moderate pain, acute severe pain, chronic moderate to severe pain, chronic moderate pain, or chronic severe pain.
- E95) The co-crystal for use according to any one of embodiments E81) to E94) wherein the co-crystal is comprised in a pharmaceutical composition also comprising at least a solubility enhancer polymer; wherein the solubility enhancer polymer is selected from polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer or from copovidone, povidone, cyclodextrin, polyethylene glycol and lauroyl macrogol-32 glycerides EP, preferably wherein the solubility enhancer polymer is selected from polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer or other hydrophilic polymers selected from copovidone, or povidone, most preferably wherein the solubility enhancer polymer is copovidone.
- E101) A co-crystal of (rac)-tramadol·HCl and celecoxib, or a pharmaceutically acceptable derivatives thereof, for treating pain and reducing the incidence of addiction to tramadol.
- E102) The co-crystal for use according to embodiment E101), wherein the molecular ratio between the (rac)-tramadol·HCl and celecoxib is 1:1.
- E103) The co-crystal for use according to any one of embodiments E101) or E102) comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, characterized in that the co-crystal shows a Powder X-Ray Diffraction pattern with at least one of the peaks [2 θ] selected from 7.1, 9.3, 10.2, 10.7, 13.6, 13.9, 14.1, 15.5, 16.1, 16.2, 16.8, 17.5, 18.0, 19.0, 19.5, 19.9, 20.5, 21.2, 21.3, 21.4, 21.8, 22.1, 22.6, 22.7, 23.6, 24.1, 24.4, 25.2, 26.1, 26.6, 26.8, 27.4, 27.9, 28.1, 29.1, 29.9, 30.1, 31.1, 31.3, 31.7, 32.5, 32.8, 34.4, 35.0, 35.8, 36.2 and 37.2[°], with the 2 θ values being obtained using copper radiation (CuK α 1 1.54060Å).
- E104) The co-crystal for use according to any one of embodiments E102) or E103), characterized in that the co-crystal shows a Powder X-Ray Diffraction pattern with peaks [2 θ] at:

- 14.1 and 22.7[°],
- 14.1 and 19.0[°],
- 14.1 and 16.8[°],
- 16.8 and 22.7[°], ,
- 16.8 and 19.0[°], or
- 19.0 and 22.7[°].

with the 2θ values being obtained using copper radiation (CuKα1 1.54060Å).

E105) The co-crystal for use according to any one of embodiments E102) to E104), characterized in that the co-crystal shows a Powder X-Ray Diffraction pattern with peaks [2θ] at:

- 14.1, 16.8 and 22.7[°],
- 14.1, 19.0 and 22.7[°],
- 14.1, 16.8 and 19.0[°], or
- 16.8, 19.0 and 22.7[°].

with the 2θ values being obtained using copper radiation (CuKα1 1.54060Å).

E106) The co-crystal for use according to any one of embodiments E102) to E105), characterized in that the co-crystal shows a Powder X-Ray Diffraction pattern with peaks [2θ] at 14.1, 16.8, 19.0 and 22.7[°], with the 2θ values being obtained using copper radiation (CuKα1 1.54060Å).

E107) The co-crystal for use according to embodiment E106), characterized in that the co-crystal shows additional peaks [2θ] at 7.1, 19.9 and 20.5[°].

E108) The co-crystal for use according to embodiment E107), characterized in that the co-crystal shows additional peaks [2θ] at 13.6, 13.9, 17.5, 18.0, 19.5, 21.2, 21.3, 21.8, 22.6, 23.6, 24.1, 24.4 and 26.1 [°].

E109) The co-crystal for use according to any one of embodiments E101) to E108) comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, characterized in that the co-crystal shows a Powder X-Ray Diffraction pattern with peaks [2θ] at 7.1, 9.3, 10.2, 10.7, 13.6, 13.9, 14.1, 15.5, 16.1, 16.2, 16.8, 17.5, 18.0, 19.0, 19.5, 19.9, 20.5, 21.2, 21.3, 21.4, 21.8, 22.1, 22.6, 22.7, 23.6, 24.1, 24.4, 25.2, 26.1, 26.6, 26.8, 27.4, 27.9, 28.1, 29.1, 29.9, 30.1, 31.1, 31.3, 31.7, 32.5, 32.8, 34.4, 35.0, 35.8, 36.2 and 37.2[°], with the 2θ values being obtained using copper radiation (CuKα1 1.54060Å).

E110) The co-crystal for use according to any one of embodiments E101) to E109) comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, characterized in that the co-crystal shows a Fourier Transform Infra Red pattern with absorption bands at 3481.6 (m), 3133.5 (m), 2923.0 (m), 2667.7 (m), 1596.0 (m), 1472.4 (m), 1458.0 (m), 1335.1 (m), 1288.7 (m), 1271.8 (m), 1168.7 (s), 1237.3 (m), 1168.7 (s), 1122.6 (s), 1100.9 (m), 1042.2 (m), 976.8 (m), 844.6 (m), 820.1 (m), 786.5 (m) 625.9 (m) cm⁻¹.

E111) The co-crystal for use according to any one of embodiments E101) to E110) comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, characterized in that the co-crystal has an orthorhombic unit cell with the following dimensions:

$$\begin{aligned}a &= 11.0323(7) \text{ \AA} \\b &= 18.1095(12) \text{ \AA} \\c &= 17.3206(12) \text{ \AA}.\end{aligned}$$

E112) The co-crystal for use according to any one of embodiments E101) to E111) comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, characterized in that for the co-crystal the endothermic sharp peak corresponding to the melting point has an onset at 164°C.

E113) The co-crystal for use according to any one of embodiments E101) to E112), for the treatment of acute pain, chronic pain, neuropathic pain, nociceptive pain, mild and severe to moderate pain, hyperalgesia, pain related to central sensitization, allodynia or cancer pain, including diabetic neuropathy or diabetic peripheral neuropathy and osteoarthritis, fibromyalgia; rheumatoid arthritis, ankylosing spondylitis, frozen shoulder or sciatica.

E114) The co-crystal for use according to any one of embodiments E101) to E113), for the treatment of acute and chronic moderate to severe pain, acute moderate to severe pain, acute moderate pain, acute severe pain, chronic moderate to severe pain, chronic moderate pain, or chronic severe pain.

E115) The co-crystal for use according to any one of embodiments E101) to E114) wherein the co-crystal is comprised in a pharmaceutical composition also comprising at least a solubility enhancer polymer; wherein the solubility enhancer polymer is

selected from polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer or from copovidone, povidone, cyclodextrin, polyethylene glycol and lauroyl macrogol-32 glycerides EP, preferably wherein the solubility enhancer polymer is selected from polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer or other hydrophilic polymers selected from copovidone, or povidone, most preferably wherein the solubility enhancer polymer is copovidone.

- E121) A co-crystal of (rac)-tramadol·HCl and celecoxib, or a pharmaceutically acceptable derivatives thereof, for treating pain and reducing the likelihood that the treatment will cause an addiction to tramadol.
- E122) The co-crystal for use according to embodiment E121), wherein the molecular ratio between the (rac)-tramadol·HCl and celecoxib is 1:1.
- E123) The co-crystal for use according to any one of embodiments E121) or E122) comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, characterized in that the co-crystal shows a Powder X-Ray Diffraction pattern with at least one of the peaks [2 θ] selected from 7.1, 9.3, 10.2, 10.7, 13.6, 13.9, 14.1, 15.5, 16.1, 16.2, 16.8, 17.5, 18.0, 19.0, 19.5, 19.9, 20.5, 21.2, 21.3, 21.4, 21.8, 22.1, 22.6, 22.7, 23.6, 24.1, 24.4, 25.2, 26.1, 26.6, 26.8, 27.4, 27.9, 28.1, 29.1, 29.9, 30.1, 31.1, 31.3, 31.7, 32.5, 32.8, 34.4, 35.0, 35.8, 36.2 and 37.2[°], with the 2 θ values being obtained using copper radiation (CuK α 1 1.54060Å).
- E124) The co-crystal for use according to any one of embodiments E122) or E123), characterized in that the co-crystal shows a Powder X-Ray Diffraction pattern with peaks [2 θ] at:
- 14.1 and 22.7[°],
 - 14.1 and 19.0[°],
 - 14.1 and 16.8[°],
 - 16.8 and 22.7[°],
 - 16.8 and 19.0[°], or
 - 19.0 and 22.7[°],
- with the 2 θ values being obtained using copper radiation (CuK α 1 1.54060Å).
- E125) The co-crystal for use according to any one of embodiments E122) to E124), characterized in that the co-crystal shows a Powder X-Ray Diffraction pattern with peaks [2 θ] at:

- 14.1, 16.8 and 22.7[°],
- 14.1, 19.0 and 22.7[°],
- 14.1, 16.8 and 19.0[°], or
- 16.8, 19.0 and 22.7[°].

with the 2θ values being obtained using copper radiation ($\text{CuK}\alpha 1$ 1.54060Å).

- E126) The co-crystal for use according to any one of embodiments E122) to E125), characterized in that the co-crystal shows a Powder X-Ray Diffraction pattern with peaks [2θ] at 14.1, 16.8, 19.0 and 22.7[°], with the 2θ values being obtained using copper radiation ($\text{CuK}\alpha 1$ 1.54060Å).
- E127) The co-crystal for use according to embodiment E126), characterized in that the co-crystal shows additional peaks [2θ] at 7.1, 19.9 and 20.5[°].
- E128) The co-crystal for use according to embodiment E127), characterized in that the co-crystal shows additional peaks [2θ] at 13.6, 13.9, 17.5, 18.0, 19.5, 21.2, 21.3, 21.8, 22.6, 23.6, 24.1, 24.4 and 26.1 [°].
- E129) The co-crystal for use according to any one of embodiments E121) to E128) comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, characterized in that the co-crystal shows a Powder X-Ray Diffraction pattern with peaks [2θ] at 7.1, 9.3, 10.2, 10.7, 13.6, 13.9, 14.1, 15.5, 16.1, 16.2, 16.8, 17.5, 18.0, 19.0, 19.5, 19.9, 20.5, 21.2, 21.3, 21.4, 21.8, 22.1, 22.6, 22.7, 23.6, 24.1, 24.4, 25.2, 26.1, 26.6, 26.8, 27.4, 27.9, 28.1, 29.1, 29.9, 30.1, 31.1, 31.3, 31.7, 32.5, 32.8, 34.4, 35.0, 35.8, 36.2 and 37.2[°], with the 2θ values being obtained using copper radiation ($\text{CuK}\alpha 1$ 1.54060Å).
- E130) The co-crystal for use according to any one of embodiments E121) to E129) comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, characterized in that the co-crystal shows a Fourier Transform Infra Red pattern with absorption bands at 3481.6 (m), 3133.5 (m), 2923.0 (m), 2667.7 (m), 1596.0 (m), 1472.4 (m), 1458.0 (m), 1335.1 (m), 1288.7 (m), 1271.8 (m), 1168.7 (s), 1237.3 (m), 1168.7 (s), 1122.6 (s), 1100.9 (m), 1042.2 (m), 976.8 (m), 844.6 (m), 820.1 (m), 786.5 (m) 625.9 (m) cm^{-1} .

- E131) The co-crystal for use according to any one of embodiments E121) to E130) comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, characterized in that the co-crystal has an orthorhombic unit cell with the following dimensions:

$$a = 11.0323(7) \text{ \AA}$$

$$b = 18.1095(12) \text{ \AA}$$

$$c = 17.3206(12) \text{ \AA}.$$

- E132) The co-crystal for use according to any one of embodiments E121) to E131) comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, characterized in that for the co-crystal the endothermic sharp peak corresponding to the melting point has an onset at 164°C.
- E133) The co-crystal for use according to any one of embodiments E121) to E132), for the treatment of acute pain, chronic pain, neuropathic pain, nociceptive pain, mild and severe to moderate pain, hyperalgesia, pain related to central sensitization, allodynia or cancer pain, including diabetic neuropathy or diabetic peripheral neuropathy and osteoarthritis, fibromyalgia; rheumatoid arthritis, ankylosing spondylitis, frozen shoulder or sciatica.
- E134) The co-crystal for use according to any one of embodiments E121) to E133), for the treatment of acute and chronic moderate to severe pain, acute moderate to severe pain, acute moderate pain, acute severe pain, chronic moderate to severe pain, chronic moderate pain, or chronic severe pain.
- E135) The co-crystal for use according to to any one of embodiments E121) to E134) wherein the co-crystal is comprised in a pharmaceutical composition also comprising at least a solubility enhancer polymer; wherein the solubility enhancer polymer is selected from polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer or from copovidone, povidone, cyclodextrin, polyethylene glycol and lauroyl macrogol-32 glycerides EP, preferably wherein the solubility enhancer polymer is selected from polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer or other hydrophilic polymers selected from copovidone, or povidone, most preferably wherein the solubility enhancer polymer is copovidone.

CLAIMS:


1. A co-crystal of (rac)-tramadol·HCl and celecoxib, or a pharmaceutically acceptable derivatives thereof, for use in the treatment of pain while reducing the abuse liability of tramadol.
2. The co-crystal for use according to claim 1, wherein the molecular ratio between the (rac)-tramadol·HCl and celecoxib is 1:1.
3. The co-crystal for use according to any one of claims 1 or 2 comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, characterized in that the co-crystal shows a Powder X-Ray Diffraction pattern with at least one of the peaks [2 θ] selected from 7.1, 9.3, 10.2, 10.7, 13.6, 13.9, 14.1, 15.5, 16.1, 16.2, 16.8, 17.5, 18.0, 19.0, 19.5, 19.9, 20.5, 21.2, 21.3, 21.4, 21.8, 22.1, 22.6, 22.7, 23.6, 24.1, 24.4, 25.2, 26.1, 26.6, 26.8, 27.4, 27.9, 28.1, 29.1, 29.9, 30.1, 31.1, 31.3, 31.7, 32.5, 32.8, 34.4, 35.0, 35.8, 36.2 and 37.2[°], with the 2 θ values being obtained using copper radiation (CuK α 1 1.54060Å).
4. The co-crystal for use according to any one of claims 2 or 3, characterized in that the co-crystal shows a Powder X-Ray Diffraction pattern with peaks [2 θ] at 14.1, 16.8, 19.0 and 22.7[°], with the 2 θ values being obtained using copper radiation (CuK α 1 1.54060Å).
5. The co-crystal for use according to claim 4, characterized in that the co-crystal shows additional peaks [2 θ] at 7.1, 19.9 and 20.5[°].
6. The co-crystal for use according to claim 5, characterized in that the co-crystal shows additional peaks [2 θ] at 13.6, 13.9, 17.5, 18.0, 19.5, 21.2, 21.3, 21.8, 22.6, 23.6, 24.1, 24.4 and 26.1 [°].
7. The co-crystal for use according to any one of claims 1 to 6 comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, characterized in that the co-crystal shows a Powder X-Ray Diffraction pattern with peaks [2 θ] selected from at 7.1, 9.3, 10.2, 10.7, 13.6, 13.9, 14.1, 15.5, 16.1, 16.2, 16.8, 17.5, 18.0, 19.0, 19.5, 19.9, 20.5, 21.2, 21.3, 21.4, 21.8, 22.1, 22.6, 22.7, 23.6, 24.1, 24.4, 25.2, 26.1, 26.6, 26.8, 27.4, 27.9, 28.1, 29.1, 29.9, 30.1, 31.1, 31.3, 31.7, 32.5, 32.8, 34.4, 35.0, 35.8, 36.2 and 37.2[°], with the 2 θ values being obtained using copper radiation (CuK α 1 1.54060Å).

8. The co-crystal for use according to any one of claims 1 to 7 comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, characterized in that the co-crystal shows a Fourier Transform Infra Red pattern with absorption bands at 3481.6 (m), 3133.5 (m), 2923.0 (m), 2667.7 (m), 1596.0 (m), 1472.4 (m), 1458.0 (m), 1335.1 (m), 1288.7 (m), 1271.8 (m), 1168.7 (s), 1237.3 (m), 1168.7 (s), 1122.6 (s), 1100.9 (m), 1042.2 (m), 976.8 (m), 844.6 (m), 820.1 (m), 786.5 (m) 625.9 (m) cm^{-1} .
9. The co-crystal for use according to any one of claims 1 to 8 comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, characterized in that the co-crystal has an orthorhombic unit cell with the following dimensions:
- $a = 11.0323(7) \text{ \AA}$
 $b = 18.1095(12) \text{ \AA}$
 $c = 17.3206(12) \text{ \AA}$.
10. The co-crystal for use according to any one of claims 1 to 9 comprising (rac)-tramadol·HCl and celecoxib in a molecular ratio of 1:1, characterized in that for the co-crystal the endothermic sharp peak corresponding to the melting point has an onset at 164°C .
11. The co-crystal for use according to any one of claims 1 to 10, in the treatment of acute pain, chronic pain, neuropathic pain, nociceptive pain, mild and severe to moderate pain, hyperalgesia, pain related to central sensitization, allodynia or cancer pain, including diabetic neuropathy or diabetic peripheral neuropathy and osteoarthritis, fibromyalgia; rheumatoid arthritis, ankylosing spondylitis, frozen shoulder or sciatica.
12. The co-crystal for use according to any one of claims 1 to 11 wherein the pain is acute and chronic moderate to severe pain, acute moderate to severe pain, acute moderate pain, acute severe pain, chronic moderate to severe pain, chronic moderate pain, or chronic severe pain.
13. The co-crystal for use according to any one of claims 1 to 12 wherein the co-crystal is comprised in a pharmaceutical composition also comprising at least a solubility enhancer polymer; wherein the solubility enhancer polymer is selected from polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer or from copovidone, povidone, cyclodextrin, polyethylene glycol and lauroyl macrogol-32 glycerides EP, preferably wherein the solubility enhancer polymer is selected from polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer or other hydrophilic

polymers selected from copovidone, or povidone, most preferably wherein the solubility enhancer polymer is copovidone.

Figure 1

Plasma Linear profile of the mean for tramadol (upper) and O-desmethytramadol (down)




Treatment-1: 2 x 100 mg Co-crystal E-58425 tablets, administered alone

Treatment-2: 2 x 50 mg Tramadol HCl tablets (Ultram®), administered alone

Treatment-4: 2 x 50 mg Tramadol tablets (Ultram®) and 1 x 100 mg Celecoxib capsule (Celebrex®), taken concomitantly.

Figure 2

Abuse Quotient (tantlyalone amadol and O-desmethyltramadol (M1) after single oral administration of co-crystal E-58425, Ultram[®] and Ultram[®] + Celebrex[®]



INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2020/063250

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K31/135 A61K31/415 A61P29/00
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, BIOSIS, CHEM ABS Data, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2011/151080 A1 (ESTEVE LABOR DR [ES]; SOLER RANZANI LUIS [ES] ET AL.) 8 December 2011 (2011-12-08) cited in the application claims 1-5	1-13
A	EP 2 586 432 A2 (ESTEVE LABOR DR [ES]) 1 May 2013 (2013-05-01) claims 6-8,14,15 ----- -/--	1-13



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

15 July 2020

Date of mailing of the international search report

23/07/2020

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Werner, Doris

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2020/063250

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SEBASTIÁN VIDE LA ET AL: "Single-dose pharmacokinetics of co-crystal of tramadol-celecoxib: Results of a four-way randomized open-label phase I clinical trial in healthy subjects", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY., vol. 83, no. 12, 20 September 2017 (2017-09-20), pages 2718-2728, XP055636240, GB ISSN: 0306-5251, DOI: 10.1111/bcp.13395 abstract page 2722; table 2 page 2723; figures 3,4 -----	1-13
A	Helendooner ET AL: "Pharmacokinetics of Tramadol and Celecoxib in Japanese and Caucasian Subjects Following Administration of Co-Crystal of Tramadol-Celecoxib (CTC): A Randomised, Open-Label Study", European Journal of Drug Metabolism and Pharmacokinetics, 28 June 2018 (2018-06-28), pages 63-75, XP055636279, Retrieved from the Internet: URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394644/pdf/13318_2018_Article_491.pdf [retrieved on 2019-10-28] abstract -----	1-13
A	EP 2 349 238 A1 (ESTEVE LABOR DR [ES]) 3 August 2011 (2011-08-03) claims 1,10 -----	1-13
A	CARMEN ALMANSA ET AL: "): A Novel API-API Co-crystal for the Treatment of Pain", CRYSTAL GROWTH & DESIGN., vol. 17, no. 4, 20 March 2017 (2017-03-20), pages 1884-1892, XP055636403, US ISSN: 1528-7483, DOI: 10.1021/acs.cgd.6b01848 abstract page 1890 - page 1891 -----	1-10
A	JP 2017 190328 A (SHIONOGI & CO) 19 October 2017 (2017-10-19) claims ----- -/-	1-13

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2020/063250

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JOSÉ LÓPEZ-CEDRÚN ET AL: "Co-crystal of Tramadol-Celecoxib in Patients with Moderate to Severe Acute Post-surgical Oral Pain: A Dose-Finding, Randomised, Double-Blind, Placebo- and Active-Controlled, Multicentre, Phase II Trial", DRUGS IN R AND D, vol. 18, no. 2, 25 May 2018 (2018-05-25), pages 137-148, XP055636679, ISSN: 1174-5886, DOI: 10.1007/s40268-018-0235-y abstract -----	1-13

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2020/063250

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2011151080	A1	08-12-2011	AR 081774 A1 17-10-2012
			AU 2011260608 A1 22-11-2012
			BR 112012030704 A2 13-09-2016
			CA 2798090 A1 08-12-2011
			CN 102946871 A 27-02-2013
			CO 6660469 A2 30-04-2013
			CY 1118813 T1 07-03-2018
			DK 2575778 T3 18-04-2017
			EC SP13012368 A 31-01-2013
			EP 2392319 A1 07-12-2011
			EP 2575778 A1 10-04-2013
			EP 3158994 A1 26-04-2017
			ES 2622192 T3 05-07-2017
			HR P20170594 T1 16-06-2017
			HU E033999 T2 29-01-2018
			IL 222731 A 31-05-2016
			JP 5800016 B2 28-10-2015
			JP 2013530952 A 01-08-2013
			KR 20130093015 A 21-08-2013
			LT 2575778 T 10-04-2017
			MX 351507 B 18-10-2017
			MY 156859 A 15-04-2016
			NZ 603457 A 31-10-2014
			PL 2575778 T3 29-09-2017
			PT 2575778 T 21-04-2017
			RU 2012157256 A 20-07-2014
			SG 185385 A1 28-12-2012
			TN 2012000515 A1 01-04-2014
			TW 201143760 A 16-12-2011
			UA 109661 C2 25-09-2015
			US 2013109659 A1 02-05-2013
			WO 2011151080 A1 08-12-2011
			ZA 201208767 B 31-07-2013
EP 2586432	A2	01-05-2013	DK 2488169 T3 08-04-2013
			EC SP12011734 A 30-05-2012
			EP 2488169 A1 22-08-2012
			EP 2586432 A2 01-05-2013
			ES 2402112 T3 29-04-2013
			PL 2488169 T3 28-06-2013
			RU 2012120088 A 27-11-2013
			SI 2488169 T1 31-05-2013
			SM T201300048 B 09-07-2013
			TN 2012000075 A1 19-09-2013
EP 2349238	A1	03-08-2011	AU 2009304235 A1 22-04-2010
			CA 2737754 A1 22-04-2010
			CN 102186465 A 14-09-2011
			CY 1118374 T1 28-06-2017
			DK 2349238 T3 12-12-2016
			EP 2177215 A1 21-04-2010
			EP 2349238 A1 03-08-2011
			ES 2603962 T3 02-03-2017
			HR P20161526 T1 16-12-2016
			HU E030976 T2 28-06-2017
			IL 211785 A 31-07-2016
			JP 5645830 B2 24-12-2014
			JP 2012505847 A 08-03-2012

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2020/063250

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		KR 20110069860 A	23-06-2011
		LT 2349238 T	27-12-2016
		MX 336318 B	14-01-2016
		MY 156285 A	29-01-2016
		NZ 591873 A	21-12-2012
		PL 2349238 T3	30-06-2017
		PT 2349238 T	24-11-2016
		RU 2011119608 A	27-11-2012
		SM T201600439 B	10-01-2017
		UA 109534 C2	10-09-2015
		US 2011257134 A1	20-10-2011
		US 2012172398 A1	05-07-2012
		US 2014057879 A1	27-02-2014
		US 2014350110 A1	27-11-2014
		US 2015196503 A1	16-07-2015
		US 2015196504 A1	16-07-2015
		US 2017000806 A1	05-01-2017
		US 2017027965 A1	02-02-2017
		US 2019231800 A1	01-08-2019
		US 2020171055 A1	04-06-2020
		WO 2010043412 A1	22-04-2010
		ZA 201102762 B	28-12-2011

JP 2017190328 A	19-10-2017	JP 6323846 B2	16-05-2018
		JP 2017190328 A	19-10-2017
